Last Update 17:49
Tuesday, 18 December 2018

China approves 17 anti-cancer drugs for medical insurance coverage

Reuters , Wednesday 10 Oct 2018
Share/Bookmark
Views: 4347
Share/Bookmark
Views: 4347

China has approved 17 anti-cancer drugs for inclusion in its national health insurance system, the government said on Wednesday, part of its efforts to make cancer treatment more affordable as the number of cases increases.

China's State Medical Insurance Administration has been in negotiations with domestic and overseas pharmaceutical companies to lower prices and put more cancer drugs on the list of medicines eligible for reimbursement.

The administration said in a notice that the negotiations were a major part of the government's strategy to make cancer drugs more affordable to the general public. The 17 drugs, which include azacitidine, will remain eligible until Nov. 30, 2020.

China's cancer rates have been soaring, driven by growing numbers of over-60s, heavy smoking among men and exposure to pollution. The National Cancer Center said last year there were 4.29 million new cases every year and 2.81 million deaths.

China has vowed to improve the five-year cancer survival rate by 15 percentage points by 2030. The rate stood at 30 percent in 2015, half the U.S. level.

Search Keywords:
Short link:

 

Email
 
Name
 
Comment's
Title
 
Comment
Ahram Online welcomes readers' comments on all issues covered by the site, along with any criticisms and/or corrections. Readers are asked to limit their feedback to a maximum of 1000 characters (roughly 200 words). All comments/criticisms will, however, be subject to the following code
  • We will not publish comments which contain rude or abusive language, libelous statements, slander and personal attacks against any person/s.
  • We will not publish comments which contain racist remarks or any kind of racial or religious incitement against any group of people, in Egypt or outside it.
  • We welcome criticism of our reports and articles but we will not publish personal attacks, slander or fabrications directed against our reporters and contributing writers.
  • We reserve the right to correct, when at all possible, obvious errors in spelling and grammar. However, due to time and staffing constraints such corrections will not be made across the board or on a regular basis.
Latest

© 2010 Ahram Online.